Abstract
Background
It is not clear which screening examinations are best suited for gastric cancer prevention, especially in patients with atrophic gastritis and intestinal metaplasia. Therefore, we investigated the gastric cancer screening methods and intervals that are performed in clinical practice in an area with a high prevalence of gastric cancer.
Methods
Eighty-seven physicians voted by keypad and discussed the consistency of endoscopic diagnosis of atrophic gastritis and intestinal metaplasia at the Annual Symposium of the Korean College of Helicobacter and Upper Gastrointestinal Research. Additionally, 100 core members of this academic society were asked via e-mail to complete the questionnaires related to screening strategies for gastric cancer.
Results
The most common recommendation for the subjects with intestinal metaplasia was an annual endoscopic follow-up (95.5% vs. 80.4% in the expert and non-expert groups, respectively; P = 0.118). Annual endoscopic follow-up was also the most predominant recommendation for atrophic gastritis (95.5% vs. 76.5%; P = 0.092), regardless of the physicians’ endoscopic experience, position, and degree of the hospital. However, the correct answer rate for the diagnosis of normal endoscopic findings was only 16.7 and 14.1% in the expert and non-expert groups, respectively (P = 0.883).
Conclusions
The most common practical screening strategy for patients with atrophic gastritis and intestinal metaplasia in Korea was annual endoscopic examination. However, a new program estimating individualized gastric cancer risk might be needed because of the low inter-observer agreement in the endoscopic diagnosis of atrophic gastritis and intestinal metaplasia.
Similar content being viewed by others
References
Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735–6740.
Lahner E, Bordi C, Cattaruzza MS, et al. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther. 2005;22:471–481.
de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter. 2007;12:1–15.
Filipe MI, Muñoz N, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer. 1994;57:324–329.
You WC, Li JY, Blot WJ, et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer. 1999;83:615–619.
Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–789.
Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut. 1991;32:1110–1113.
Leung WK, Sung JJ. Review article: intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther. 2002;16:1209–1216.
Yearly report of Korea on cancer development (2007.1.1–2007.12.31). Ministry of Health and Welfare for the Korean Government 2010.
Kim HJ, Choi BY, Byun TJ, et al. The prevalence of atrophic gastritis and intestinal metaplasia according to gender, age and Helicobacter pylori infection in a rural population. J Prev Med Public Health. 2008;41:373–379.
Whiting JL, Sigurdsson A, Rowlands DC, et al. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut. 2002;50:378–381.
Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, et al. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol. 2004;57:177–182.
Lahner E, Caruana P, D’Ambra G, et al. First endoscopic-histologic follow-up in patients with body-predominant atrophic gastritis: when should it be done? Gastrointest Endosc. 2001;53:443–448.
de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134:945–952.
Kim YS, Park HA, Kim BS, et al. Efficacy of screening for gastric cancer in a Korean adult population: a case–control study. J Korean Med Sci. 2000;15:510–515.
Nam SY, Choi IJ, Park KW, et al. Effect of repeated endoscopic screening on the incidence and treatment of gastric cancer in health screenees. Eur J Gastroenterol Hepatol. 2009;21:855–860.
Shiratori Y, Nakagawa S, Kikuchi A, et al. Significance of a gastric mass screening survey. Am J Gastroenterol. 1985;80:831–834.
Tsubono Y, Hisamichi S. Screening for gastric cancer in Japan. Gastric Cancer. 2000;3:9–18.
Mori Y, Arita T, Shimoda K, et al. Effect of periodic endoscopy for gastric cancer on early detection and improvement of survival. Gastric Cancer. 2001;4:132–136.
Tashiro A, Sano M, Kinameri K, et al. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol. 2006;12:4873–4874.
Dan YY, So JB, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol. 2006;4:709–716.
Park MJ, Kim DH, Lim SH, et al. Features of gastric neoplasm detected during the screening examination. Gut Liver. 2007;1:33–39.
Lee KJ, Inoue M, Otani T, et al. Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer. 2006;118:2315–2321.
Kunisaki C, Ishino J, Nakajima S, et al. Outcomes of mass screening for gastric carcinoma. Ann Surg Oncol. 2006;13:221–228.
Miyamoto A, Kuriyama S, Nishino Y, et al. Lower risk of death from gastric cancer among participants of gastric cancer screening in Japan: a population-based cohort study. Prev Med. 2007;44:12–19.
Yoshida S, Yamaguchi H, Tajiri H, et al. Diagnosis of early gastric cancer seen as less malignant endoscopically. Jpn J Clin Oncol. 1984;14:225–241.
Hosokawa O, Miyanaga T, Kaizaki Y, et al. Decreased death from gastric cancer by endoscopic screening: association with a population-based cancer registry. Scand J Gastroenterol. 2008;43:1112–1115.
Carpenter HA, Talley NJ. Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology. 1995;108:917–924.
Redéen S, Petersson F, Jönsson KA, et al. Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample. Endoscopy. 2003;35:946–950.
Lin BR, Shun CT, Wang TH, et al. Endoscopic diagnosis of intestinal metaplasia of stomach—accuracy judged by histology. Hepatogastroenterology. 1999;46:162–166.
Graham DY, Rugge M. Clinical practice: diagnosis and evaluation of dyspepsia. J Clin Gastroenterol. 2010;44:167–172.
Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007;56:631–636.
Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol. 1976;38:46–51.
Chang MC, Oh SK. Development of individual probabilities estimating program of major cancer in Koreans. J Korean Soc Med Inform. 2008;14:355–371.
Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005;54:764–768.
Mukoubayashi C, Yanaoka K, Ohata H, et al. Serum pepsinogen and gastric cancer screening. Intern Med. 2007;46:261–266.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Shin, W.G., Kim, H.U., Song, H.J. et al. Surveillance Strategy of Atrophic Gastritis and Intestinal Metaplasia in a Country with a High Prevalence of Gastric Cancer. Dig Dis Sci 57, 746–752 (2012). https://doi.org/10.1007/s10620-011-1919-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-011-1919-0